Not all pathogenetic variants associated with prostate cancer have the same mutagenic potential, that is, penetrance and a previous expert panel consensus recommendation has advocated for priority testing of BRCA2/1 and DNA mismatch repair (MMR) genes over other variants (57). The gene discussed is BRCA2; the disease is prostate cancer.